NCT04068896: A trial that was reported late by NGM Biopharmaceuticals, Inc
This trial has reported, although it was 164 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04068896 |
|---|---|
| Title | A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 16, 2019 |
| Completion date | Sept. 21, 2023 |
| Required reporting date | Sept. 20, 2024, midnight |
| Actual reporting date | March 4, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 164 |